Patents by Inventor Amato J. Giaccia

Amato J. Giaccia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • sPD-1 VARIANT – FC FUSION PROTEINS
    Publication number: 20230131056
    Abstract: The invention is directed to novel sPD-1 variant-Fc fusion proteins.
    Type: Application
    Filed: October 10, 2022
    Publication date: April 27, 2023
    Applicants: The Board of Trustees of the Leland Stanford Junior University, AKSO Biopharmaceutical, Inc.
    Inventors: Amato J. Giaccia, Todd A. Aguilera, Mihalis S. Kariolis, Yu Miao, Kaushik Thakkar, Xin Eric Zhang
  • RECEPTOR-BASED ANTAGONISTS OF THE PROGRAMMED CELL DEATH 1 (PD-1) PATHWAY
    Publication number: 20220378873
    Abstract: Provided herein are compositions and methods for alleviating cancer or infection in a subject by administering a therapeutically effective amount of a pharmaceutical composition comprising an isolated PD-1 variant polypeptide. The PD-1 variant polypeptide can inhibit the activity of PD-1 by, for example, competitive or non-competitive inhibition of the interaction between wild-type PD-1 and one or more of its ligands, PD-L1 and PD-L2.
    Type: Application
    Filed: June 24, 2022
    Publication date: December 1, 2022
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Amato J. GIACCIA, Mihalis S. KARIOLIS, Todd A. AGUILERA
  • SPD-1 variant# FC fusion proteins
    Patent number: 11498955
    Abstract: The invention is directed to novel sPD-1 variant—Fc fusion proteins.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: November 15, 2022
    Assignees: The Board of Trustees of the Leland Stanford Junior University, AKSO Biopharmaceutical, Inc.
    Inventors: Amato J. Giaccia, Todd A. Aguilera, Mihalis S. Kariolis, Yu Miao, Kaushik Thakkar, Xin Eric Zhang
  • Hypoxia Targeting Compositions and Combinations Thereof with a PARP Inhibitor and Methods of Use Thereof
    Publication number: 20220249522
    Abstract: Methods for treating a cancer are provided, the methods comprising administering to an individual an effective amount of a hypoxia targeting composition, such as a hypoxia-activated drug or a prodrug thereof, and combinations thereof with an effective amount of a poly(ADP-ribose) polymerase (PARP) inhibitor. In some instances, one or more of a homology recombination (HR) efficiency status, an IDH mutation status, and a hypoxia status of a cancer is used as a basis for selecting an individual for a treatment disclosed herein. Also provided are compositions (such as pharmaceutical formulations), medicine, kits, and unit dosages useful for the methods described herein.
    Type: Application
    Filed: December 6, 2019
    Publication date: August 11, 2022
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Manal Mehibel, Amato J. Giaccia
  • Receptor-based antagonists of the programmed cell death 1 (PD-1) pathway
    Patent number: 11400133
    Abstract: Provided herein are compositions and methods for alleviating cancer or infection in a subject by administering a therapeutically effective amount of a pharmaceutical composition comprising an isolated PD-1 variant polypeptide. The PD-1 variant polypeptide can inhibit the activity of PD-1 by, for example, competitive or non-competitive inhibition of the interaction between wild-type PD-1 and one or more of its ligands, PD-L1 and PD-L2.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: August 2, 2022
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Amato J. Giaccia, Mihalis S. Kariolis, Todd A. Aguilera
  • Modified AXL Peptides and Their Use in Inhibition of AXL Signaling in Anti-Metastatic Therapy
    Publication number: 20220220458
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Application
    Filed: September 2, 2021
    Publication date: July 14, 2022
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Cynthia Fuh, Yu Miao, Susan Hershenson
  • Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
    Patent number: 11136563
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: October 5, 2021
    Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, ARAVIVE BIOLOGICS, INC.
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Cynthia Fuh, Yu Miao, Susan Hershenson
  • Antifibrotic activity of GAS6 inhibitor
    Patent number: 10876176
    Abstract: Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: December 29, 2020
    Assignees: Aravive Biologics, Inc., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Raymond Tabibiazar, Amato J. Giaccia, Mihalis Kariolis, Yu Rebecca Miao
  • RECEPTOR-BASED ANTAGONISTS OF THE PROGRAMMED CELL DEATH 1 (PD-1) PATHWAY
    Publication number: 20200360474
    Abstract: Provided herein are compositions and methods for alleviating cancer or infection in a subject by administering a therapeutically effective amount of a pharmaceutical composition comprising an isolated PD-1 variant polypeptide. The PD-1 variant polypeptide can inhibit the activity of PD-1 by, for example, competitive or non-competitive inhibition of the interaction between wild-type PD-1 and one or more of its ligands, PD-L1 and PD-L2.
    Type: Application
    Filed: February 7, 2020
    Publication date: November 19, 2020
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Amato J. Giaccia, Mihalis S. Kariolis, Todd A. Aguilera
  • sPD-1 VARIANT - FC FUSION PROTEINS
    Publication number: 20200181231
    Abstract: The invention is directed to novel sPD-1 variant—Fc fusion proteins.
    Type: Application
    Filed: September 12, 2019
    Publication date: June 11, 2020
    Applicants: The Board of Trustees of the Leland Stanford Junior University, AKSO Biopharmaceutical, Inc.
    Inventors: Amato J. Giaccia, Todd A. Aguilera, Mihalis S. Kariolis, Yu Miao, Kaushik Thakkar, Xin Eric Zhang
  • Receptor-based antagonists of the programmed cell death 1 (PD-1) pathway
    Patent number: 10588938
    Abstract: Provided herein are compositions and methods for alleviating cancer or infection in a subject by administering a therapeutically effective amount of a pharmaceutical composition comprising an isolated PD-1 variant polypeptide. The PD-1 variant polypeptide can inhibit the activity of PD-1 by, for example, competitive or non-competitive inhibition of the interaction between wild-type PD-1 and one or more of its ligands, PD-L1 and PD-L2.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: March 17, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Amato J. Giaccia, Mihalis S. Kariolis, Todd A. Aguilera
  • MODULATION OF AXL RECEPTOR ACTIVITY IN COMBINATION WITH CYTOREDUCTIVE THERAPY
    Publication number: 20180140679
    Abstract: Compositions and methods are provided for treating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL protein activity, for example by inhibition of the binding interaction between AXL and its ligand GAS6. The treatment may be combined with a cytoreductive therapy.
    Type: Application
    Filed: November 20, 2017
    Publication date: May 24, 2018
    Inventors: Amato J. Giaccia, Jennifer R. Cochran, Yu Miao, Mihalis Kariolis
  • Receptor-Based Antagonists of the Programmed Cell Death 1 (PD-1) Pathway
    Publication number: 20180125934
    Abstract: Provided herein are compositions and methods for alleviating cancer or infection in a subject by administering a therapeutically effective amount of a pharmaceutical composition comprising an isolated PD-1 variant polypeptide. The PD-1 variant polypeptide can inhibit the activity of PD-1 by, for example, competitive or non-competitive inhibition of the interaction between wild-type PD-1 and one or more of its ligands, PD-L1 and PD-L2.
    Type: Application
    Filed: October 2, 2017
    Publication date: May 10, 2018
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Amato J. Giaccia, Mihalis S. Kariolis, Todd A. Aguilera
  • INHIBITION OF AXL/GAS6 SIGNALING IN THE TREATMENT OF LIVER FIBROSIS
    Publication number: 20180094034
    Abstract: Compositions and methods are provided for alleviating endometriosis, kidney disease, inflammatory disease and/or transplant rejection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 5, 2018
    Inventors: Patrick O'Connor, Raymond Tabibiazar, Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
  • ANTIFIBROTIC ACTIVITY OF GAS6 INHIBITOR
    Publication number: 20180057898
    Abstract: Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Application
    Filed: December 17, 2015
    Publication date: March 1, 2018
    Inventors: Raymond Tabibiazar, Amato J. Giaccia, Mihalis Kariolis, Yu Rebecca Miao
  • MODIFIED AXL PEPTIDES AND THEIR USE IN INHIBITION OF AXL SIGNALING IN ANTI-METASTATIC THERAPY
    Publication number: 20180030422
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Application
    Filed: October 13, 2017
    Publication date: February 1, 2018
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Cynthia Fuh, Yu Miao, Susan Hershenson
  • Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
    Patent number: 9879061
    Abstract: Compositions and methods are provided for alleviating endometriosis, kidney disease, inflammatory disease and/or transplant rejection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: January 30, 2018
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Aravive Biologics, Inc.
    Inventors: Patrick O'Connor, Raymond Tabibiazar, Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
  • Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
    Patent number: 9822347
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: November 21, 2017
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Aravive Biologics, Inc.
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao, Susan Hershenson
  • HIGH-AFFINITY BINDING TO GAS6
    Publication number: 20160266136
    Abstract: Compositions and methods are provided for measuring the amount of GAS6 in a sample. Also provided are compositions and methods related to high-affinity CAS6 inhibitor agents that induce a conformational change of GAS6 that stabilizes Helix A of GAS6.
    Type: Application
    Filed: December 12, 2013
    Publication date: September 15, 2016
    Inventors: Jennifer R. Cochran, Amato J. Giaccia, Yu Miao, Mihalis Kariolis, Shiven Kapur, Irimpan I. Mathews
  • Inhibition of AXL Signaling in Anti-Metastatic Therapy
    Publication number: 20160108378
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
    Type: Application
    Filed: May 14, 2015
    Publication date: April 21, 2016
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao